Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...

Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.

In this article, we are going to take a look at where Sanofi (NASDAQ ... stocks present lucrative investment opportunities. The market for immunotherapy medications is expected to rise at a ...

The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the ... points (see more details here). Sanofi (NASDAQ:SNY) stands seventh ...